“What does the term ‘successor-in-interest’ mean?”

Funding News Edition:
See more articles in this edition

NIH defines “successor-in-interest” as the process whereby the rights to and obligations under an NIH grant are acquired incidental to the transfer of all the assets of the recipient or the transfer of that part of the assets involved in the performance of the grant. Broadly speaking, the term applies when an NIH grantee organization is subsumed or purchased by another organization.

To complete the process of transferring rights and obligations for the grant, the organization that is incidentally acquiring the grant must submit a Type 6 application through Successor-in-Interest (Type 6, Parent Clinical Trial Optional).

Such situations are rare. More common is when a grant is transferred from the original grantee institution to a different organization, which calls for a Type 7 application through Change of Recipient Organization (Type 7, Parent Clinical Trial Optional).

Contact Us

Email us at deaweb@niaid.nih.gov for help navigating NIAID’s grant and contract policies and procedures.

Content last reviewed on